Obermatt

Kuros Biosciences

SWX:KURN · CH0325814116
BiotechnologySmall

360

80
EV / EBIT10
Price / Owner Earnings1
Owner Earnings Yield91
Dividend Yield1
Price/Sales46
EV / Gross Profit52
Price/Book7
Return on Capital88
Cash Return on Capital95
Return on Equity87
EBIT Margin67
Gross Profitability100
Accruals31
Owner Earnings Margin89
Sales growth71
Profit Growth69
Long-Term EPS Growth67
Reinvestment80
Price momentum27
Debt load83
Refinancing65
Debt Payback100
Liquidity90
Analyst ratings54
Opinion Changes50
Price Target Upside39
Market mood3
Value Creation14/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Kuros Biosciences generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountrySwitzerland
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeSWX
Founded2016
Employees173
ISINCH0325814116
Last UpdateApr 2, 2026
Themes
OrthopaedicsBiomedical EngineeringBiopharmaBiotechnologyHealth CareMedical

Description

Kuros Biosciences AG a biopharmaceutical company that engages in the development and commercialization for tissue repair and bone regeneration products. Business Segments The company operates through Medical Devices, Pharmaceuticals, and Legacy Por…

Analysis

Quality compounder

Kuros Biosciences AG is a quality compounder: a well-run business trading at a price that reflects what it is worth. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is expensive. You pay 368.5× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is moderate and the balance sheet is sturdy. The company scores 14/20 on our value-creation score: strong value creator.

What to watch: Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
27
2026

All-time high

80

Mar 2026

All-time low

27

Jun 2026

Average rank

54

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
46
Price/Earnings
1
Price/Book
7
Dividend Yield
1
Value (overall)
1

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Kuros Biosciences with its peers
Zealand Pharma
CPH:ZEAL
78
CountryDenmark
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Mereo BioPharma Group
NAQ:MREO
51
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
ABIVAX
PAR:ABVX
26
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immunovant
NSQ:IMVT
86
CountryUK
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
AC Immune
NMQ:ACIU
68
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Galapagos
AEX:GLPG
76
CountryBelgium
IndustryBiotechnology
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →